Kornimate/medical-research-clean huggingface dataset:
prospective observational study to evaluate the safety of immunotherapy as a treatment for hymenoptera venom allergy

Conditions: Allergy, Insect Venom; Allergy Insect Stinging; Insect Sting Allergy

Summary: observational study to evaluate the safety of immunotherapy as a treatment for hymenoptera venom allergy, analyzing the adverse reaction to immunotherapy as well as the allergic reaction to a spontaneous hymenoptera sting. this study will be conducted in spain (multicentric) and data will be collected prospectively.

observational study to evaluate the adverse reaction to immunotherapy as well as the allergic reaction to a spontaneous hymenoptera sting (safety evaluation), also it will be evulated the quality of life of the patient using one qol questionnair before and after immunotherapy treatment. the patients aged equal or more than 14 years old, not gender differentiation, and sensitised to heminoptera venom. the total number of participants is expected to be 120. this study will be conducted in spain (multicentric) and data will be collected prospectively.

Eligibility criteria:
inclusion criteria: 1. the study population consisted of allergic participants indicated for treatment with immunotherapy with hymenoptera venom (apis mellifera or vespula spp.) according to standard clinical practice. 2. age equal to or older than 14 years, without gender differences. 3. not having received immunotherapy with hymenoptera venom in the previous 5 years. 4. that they agree to participate in the study and sign the informed consent form. in the case of minors, the parent or guardian of the participant must also sign the informed consent form. exclusion criteria: 1. pregnant or breastfeeding women. 2. having received immunotherapy with hymenoptera venom during the 5 years prior to the start of the study. 3. participants who do not agree to participate and/or do not sign the informed consent form. 4. participants who do not comply with the medical indications or do not show cooperation with respect to the immunotherapy treatment. 5. participants with oncological diseases under active treatment or with autoimmune diseases under immunosuppressive treatment. 6. participants in whom the administration of immunotherapy is contraindicated.

Keywords: allergy immunothepary apis mellifera vespula spp. insect venom
norepinephrine and phenylephrine, which better for elderly?

Conditions: Hypotension

Summary: this is a prospective, double-blinded and single-center study. this study is based on the stroke volume variation fluid guided therapy, to compare the effects of norepinephrine and phenylephrine in treating perioperative hypotension, and to find the safest and most effective vasopressor for elderly.


Eligibility criteria:
inclusion criteria: * radical resection of colorectal or gastric cancers, * age over 65 years old, * surgical time longer than 2hours, * the american society of anesthesiologists(asa) classification of ii or iii exclusion criteria: * history of severe cardiovascular diseases, * history of severe liver and kidney diseases, * evidence of arrhythmia on ekg, * use of positive end-expiratory pressure (peep) during mechanical ventilation; * conditions with relative contraindication for arterial catheterization

Keywords: goal-directed fluid therapy norepinephrine phenylephrine elderly
effect of physical activity intervention on overweight and obese patients with endometrial cancer

Conditions: Endometrium Cancer; Physical Activity; Weight Management

Summary: this study evaluated the clinical outcome of exercise management on patients with endometrial cancer treated with fertility preservation, including the effect of complete response rate, complete response time, recurrence rate, recurrence time, etc., and physical composition, to evaluate the effectiveness of physical activity on weight management.


Eligibility criteria:
inclusion criteria: * participants were patients who met the following predefined eligibility criteria: ages 20-40; overweight or obese; the pathological diagnosis was ec (endometrioid, grade i, no myometrium invasion or metastasis). not pregnant; be willing to comply with test requirements after being fully informed of all risks and inconveniences associated with the test. exclusion criteria: * recurrent or metastatic disease; currently participating in regular exercise at least 2 days per week; pregnant at the start of the study; or unwilling to comply with research requirements. patients also completed the physical activity readiness questionnaire (par-q) through a telephone interview. patients with one or more potential exercise-related safety risks were excluded.
cldn6/gpc3/mesothelin/axl-car-nk cell therapy for advanced solid tumors

Conditions: Stage IV Ovarian Cancer; Testis Cancer, Refractory; Endometrial Cancer Recurrent; CAR NK

Summary: this study is an open, exploratory clinical study to evaluate the safety and preliminary efficacy of claudin6, gpc3, mesothelin, or axl targeting car-nk cells in patients with claudin6, gpc3, mesothelin, or axl-positive advanced solid tumors (ovarian cancer and others)

1. choose appropriate advanced cancer patients with claudin6, gpc3, mesothelin, or axl expression, with written consent for the study; 2. perform pbmcs apheresis from the patient and isolate nk cells, transfect the nk cells with claudin6, gpc3, mesothelin, or axl targeting car, amplify the number of transfected nk cells as needed, test the quality and killing activity of the claudin6, gpc3, mesothelin, or axl-car-nk cells and then transplant back the patients via systemic or local infusions (via artery or intra-tumor), and follow up closely to collect related results as needed; 3. to enhance the killing capability, some car-nk cells are genetically engineered to express and secret il7/ccl19 and/or scfvs against pd1/ctla4/lag3; some car-nk cells are combined with cannabidiol(cbd) or nicotinamide adenine dinucleotide (nad); 4. evaluate the clinical results as needed. 5. will also perform the similar clinical trial on different cancer types with claudin6, gpc3, mesothelin, or axl expression.

Eligibility criteria:
inclusion criteria: 1. patients with advanced ovarian cancer or other cancers with expression of claudin6. 2. life expectancy \>12 weeks 3. adequate heart,lung,liver,kidney function 4. available autologous transduced nk cells with greater than or equal to 20% expression of claudin6, gpc3, mesothelin, or axl-car determined by flow-cytometry and killing of claudin6-positive targets greater than or equal to 20% in cytotoxicity assay 5. informed consent explained to, understood by and signed by patient/guardian. patient/guardian given copy of informed consent. - exclusion criteria: 1. had accepted gene therapy before; 2. tumor size more than 25cm; 3. severe virus infection such as hbv,hcv,hiv,et al 4. known hiv positivity 5. history of liver/renal transplantation 6. active infectious disease related to bacteria, virus,fungi,et al 7. other severe diseases that the investigators consider not appropriate; 8. pregnant or lactating women 9. systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day) 10. other conditions that the investigators consider not appropriate. -

Keywords: solid tumor claudin6 car nk gpc3 mesothelin axl cannabidiol nicotinamide adenine dinucleotide il7 ccl19 pd1 antibody pdl1 antibody ctla1 antibody
transfemoral transcatheter aortic valve implementation at hospital without on-site cardiac surgery: early clinical outcome in patients with prohibitive surgical risk.

Conditions: Aortic Stenosis

Summary: study design: single arm, interventional and multicenter study. the objectives are evaluate safety and efficacy of tavi in department of cardiology without on site cardiac surgery for symptomatic severe aortic valve stenosis by expert operator team, in patients with prohibitive surgical risk. for the pilot phase, 20 patients will be enrolled. for whole study, all consecutive patients undergoing tavi in center without cs on site will be enrolled to reach a number of about 200 patients.


Eligibility criteria:
inclusion criteria: * senile degenerative aortic valve stenosis with echocardiography derived criteria: mean gradient \> 40 mmhg or jet velocity \> 4.0 m/s aortic valve area (ava) of \< 0.8 cm2 (or ava index \< 0.5 cm2/m2) * symptomatic due to aortic valve stenosis as demonstrated by nyha functional class \> = ii * age \>= 75 years old * patients with prohibitive risk established in the heart team and defined on the basis of the following clinica instrument criteria according with the varc-2 consensus. * high surgical risk (%, loges\>20%, euroscore ii \> 9 and sts score \> 8%) * porcelain aorta (heavy circumferential calcification or severe atheromatous plaques that do not allow clamping. * hostile chest (abnormal chest wall anatomy due to severe kyphoscoliosis or other skeletal abnormalities, complications form to previous surgery, evidence of severe radiotion damege, history of multiple recurrent pleural effusions causing internal adhesions. * fragilty (slowness, weakness, exhaustion, wasting and malnutrition, poor endurance and inactivity, loss of independence, bmi \< 20 kg/m2 and or weight loss 5 kg/year, serum albumin \< 3,5 g/dl, cognitive impairment or dementia) * severe liver disease/cirrosis * presence of a patent graft of an internal mammary artery crossing mildline and/or adherent to posterior table of sternum * severe pulmoary hypertension * severe right ventricular dysfunction * transfemoral access allowed * signature of informed consent exclusion criteria: * tavi in case of aortic valve bioprosthesis (tavi valve-in valve) * controindication to femoral access * bicuspid aortic valve * instrumental characteristics, evaluated by angiotc, associated with an increased risk of major complications: severe left ventricle outflow tract or sub annular calcification, condition associated with an increased risk of rupture of the valve ring, presence of complex aortic plaques correlated with the possibility of dissection, valvular ring-coronary ostia distance \< 10 mm associated with a high probability of coronary obstruction, severe aortic root dilatation or out of range aortic annulus diameters for tavi are not complatible for safe valve implatation.
a multiple baseline design study to investigate the effectiveness of ot-si using an intensive intervention model

Conditions: Motor Coordination or Function; Developmental Disorder

Summary: the investigators hypothesize that children completing 30 sessions of occupational therapy using a sensory integration approach (ot-si) will demonstrate positive changes in outcome measures related to motor coordination, functional performance and sensory processing (changes pre-post test).


Eligibility criteria:
inclusion criteria: * have a medical diagnosis of "lack of coordination" or "other coordination impairment" * children and caregivers able to communicate verbally in english * sensory processing impairments as determined by scores in the spm-h form (screening). scores must fall in the "definite dysfunction" range in one of three categories (body awareness, balance \& motion, or planning \& ideas), or fall in the "some problems" range in 2/3 areas. exclusion criteria: * diagnosed with autism spectrum disorder or other significant psychological impairment (e.g. bipolar disorder) * receiving occupational therapy services at chor or another therapy site for more than 3 months * significant motor impairment (e.g., cerebral palsy) * significant language impairment (e.g., non-verbal, or aphasia)
effectiveness of positional release techniques and graston technique in trigger point

Conditions: Trigger Point Pain, Myofascial

Summary: the purpose of the study is to evaluate comparative effectiveness of positional release techniques and graston technique in trapezius trigger point


Eligibility criteria:
inclusion criteria: male and female age group 18-55 years at least one trigger point exclusion criteria: * radiculopathy * history of head and upper back trauma or surgery * tendency to hemorrhage * systemic disease

Keywords: trigger point trapezius pain
comparison of pain level during intrauterine device (iud) insertion between conventional and direct method

Conditions: IUD Insertion

Summary: the so-called "direct" method of intrauterine device (iud) and intraintuerine system (ius) insertion is increasingly used. a study has shown that it is technically simpler and assumes less painful than the classic pose. it seems interesting to compare the pain felt by the patients during iud / ius insertion in these two methods of placement and also to confirm that there is no more malposition with the direct method.

the classic method uses: a pozzi for pulling the uterus to horizontalize it and a hysterometer to visualize the axis of the uterus and to measure the distance between the external orifice of the cervix and the uterine fundus in order to deploy the iud / ius. in the so-called direct technique, the operator does not measure the depth of the uterus thanks to a hysterometer and does not draw the cervix with a pozzi forceps, the iud / ius is deployed as soon as the orifice passes. inside the cervix and the inserter tube does not enter the uterine cavity. with this method the pozzi forceps is only used as a second line, especially in case of a fleeing neck.

Eligibility criteria:
inclusion criteria: * the study population will concern all women aged 18 to 50 who want iud or siu contraception regardless of whether they are nulliparous, primiparous or pluriparous, whether or not they have had an iud or ius. * having signed informed consent. * being affiliated to a social security scheme (excluding ame) exclusion criteria: * can not express their consent * not mastering french * with a contraindication to the chosen iud or ius. * having had local anesthesia of the cervix (in case of voluntary interruption of pregnancy on the day of insertion) * having received analgesic treatment within four hours * patient without social security * no consent of the patient * minor patient

Keywords: pain intrauterine device (iud) intrauterine system (ius) patient-reported outcome
a study of the intervention effect of a hybrid exercise program on elderly with sarcopenia

Conditions: Sarcopenia

Summary: sarcopenia is a geriatric condition characterized by a progressive decrease in skeletal muscle content and loss of muscle function. resistance exercise, taichi exercise and the hybrid exercise program consisting of the two aforementioned methods have been demonstrated could increase the skeletal muscle mass of the elderly with sarcopenia. however, note that the above contents may be performed in a different order in a treatment, equally important but less well understood is the sequence in which it should be performed. surprisingly, the exercise sequence has not been comprehensively investigated. therefore, investigators designed a self-ordered exercise program combining resistance exercise, tai chi and a hybrid exercise program to investigate whether the decline in skeletal muscle area could be better overcome and the reversal of sarcopenia in elderly with sarcopenia.


Eligibility criteria:
inclusion criteria: 1. satisfied the asian screening criteria for sarcopenia by the asian working group for sarcopenia; 2. age higher than 60 but less than 75 years of age. exclusion criteria: 1. with serious illness or breathing failure; 2. with neuro-muscular diseases; 3. taking medication that has an effect on the function of skeletal muscles; 4. with conditions relating to the neurological system or the mental health; 5. in another scheduled training plan.

Keywords: sarcopenia elderly exercise program explainable artificial intelligence
role of uttarbasti in the management of mutra marga sankoch (urethral stricture)

Conditions: Urethral Stricture

Summary: uttarbasti is per urethral administration of medicated oil which has been recommended by sushrut for urinary track disorders. as far as conventional surgery is concerned urethral stricture still remains a challenge due to post procedural high recurrences and complications uttarbasti being almost non invasive, with minimum recurrences and most economical, easy to practice opd procedure, can be the treatment of choice in the management of urethral stricture.


Eligibility criteria:
inclusion criteria: * k/c/o urethral stricture of either sex and from all age groups. exclusion criteria: * with acute uti. * dm. * neoplasms of lower urinary tract * bep. * with impacted calculus in urethra and bladder neck.

Keywords: urethral stricture ayurvedic treatment mutra marg sankoch uttarbasti sesame oil honey rock salt
remotely programmed deep brain stimulation of the bilateral habenula for treatment- resistant major depression: an open label pilot trial

Conditions: Treatment Resistant Major Depressive Disorder

Summary: the habenula(hb) is an epithalamic structure located at the center of the dorsal diencephalic conduction system, a pathway involved in linking forebrain to midbrain regions. an increasing number of studies indicates that that overactivity in the lateral habeluna(lhb) is present during depressed states, where it could drive the changes in midbrain activity linked to depression. deep brain stimulation(dbs) of the major afferent bundle (i.e., stria medullaris thalami) of the lhb can treat treatment-resistant major depression(trd). there is no clinical case of directly stimulating habeluna for treatment trd. this research will investigate effectiveness bilateral dbs to habenula for patients with trd. programming is a crucial aspect of dbs which directly influences its therapeutic efficacy. researchers need to ascertain optimum stimulation parameters to help patients achieve optimal control of clinical symptoms. remote programming of dbs can markedly improve patient convenience, minimize risk of infection and total treatment time and lead to an overall benefit for doctors and patients alike. this research will also investigate safety and benefit of remote programming of dbs.


Eligibility criteria:
inclusion criteria: * age 18-65 years old * proficiency in mandarin language; * dsm-iv diagnosis of majior depression disorder; * current episode duration ≥ 2 years; * failure to respond to a minimum of four different antidepressant treatments; * failure or intolerance of an adequate course of electroconvulsive therapy (ect) during any episode; * capacity to provide informed consent (understanding of the study purpose and methods); exclusion criteria: * schizophrenia or history of psychosis unrelated to mdd; * antisocial personality disorder, dementia, current tic disorder; * past stereotactic neurosurgical intervention; * alcohol or substance abuse/dependence within 6 months; * neurological disease (abnormal pet-ct, mri, eeg); * contraindications of mri-examination, e.g. implanted cardiac pacemaker/ heart defibrillator; * contraindications of stereotactic intervention, e.g. increased bleeding disposition, cerebrovascular diseases; * serious and unstable organic diseases (e.g. unstable coronal heart disease); * hiv positive; * pregnancy and/or lactation;

Keywords: bilateral habeluna remote deep brain stimulation treatment resistant major depressive disorder
durability of combination therapy with exenatide/pioglitazone/metformin vs. conventional therapy in new onset t2dm

Conditions: Diabetes

Summary: type 2 diabetes is a systemic metabolic disease with significant morbidity and mortality due to damaging blood vessels. increased blood sugar level is a hallmark of diabetes and is an contributes to the development of many of its complications. multiple defects, e.g. impaired insulin secretion and impaired insulin action, contribute to the development of the disease. the aim of this study is to test the efficacy and durability of combination of drugs which correct the defects that lead to the development of diabetes on achieving adequate and durable control of blood sugar levels. achieving adequate and durable control of blood sugar will prevent many of diabetes complications.

subjects will be randomized (using a table of random numbers) to receive, in open label fashion, one of the following treatment regimens: (i) group i will be started on pioglitazone (15 mg/day) plus metformin (1000 mg/day) with the supper meal and exenatide (5 mcg s.c. bid 30 min before breakfast and supper) and up-titrated to 45 pioglitazone plus 2000 metformin and 10 mcg s.c. bid exenatide to achieve hba1c \<6.0%; (ii) group ii will be started on metformin, 1000 mg with breakfast and 1000 mg with supper, glyburide and basal insulin will be added and up titrated to achieve hba1c \<6.0% the study team will compare the efficacy of two therapeutic regimens: (i) triple therapy (pioglitazone, metformin, exenatide) at the time of diagnosis of t2dm versus (ii) stepwise therapy starting with metformin and subsequent addition of sulfonylurea and basal insulin (i.e., the "standard" approach) in achieving this goal. the first intervention is based on the novel concept of initiating therapy at the time of diagnosis with combination therapy using agents that correct specific pathophysiologic defects that are characteristic of t2dm (insulin resistance and beta cell failure). the second intervention is based upon stepwise addition of antidiabetic agents to reduce the hba1c according to the current ada therapeutic recommendation.

Eligibility criteria:
inclusion criteria: * subjects with type 2 diabetes diagnosed during the past 2 years, * above 18 years of age, * drug naive, or have been on metformin less than 3 months exclusion criteria: * subjects with type 1 diabetes or gad positive subjects or subjects with long standing diabetes (\>2 years) or subjects who are not drug naive or have been on metformin more than 3 months.

Keywords: type 2 diabetes new onset combination therapy new onset type 2 diabetes